Abernethy DR, Greenblatt DJ, Shader RI. Trimipramine kinetics and absolute bioavailability: Use of gas-liquid chromatography with nitrogen-phosphorus detection. Clin Pharmacol Ther 1984: 35(3 ), 348-353.

Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribu tion of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996: 278(1), 441-446.

Alvan G, Bertilsson L, Dahl ML, Ingelman-Sundberg M, Sjöqvist F. Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. Drug Metab Dispos 2001: 29(4 pt 2), 580-585.

Amsterdam J, Brunswick D, Mendels J. The clinical application of tricyclic antidepressant pharmaco kinetics and plasma levels. Am J Psychiatry 1980: 137(6), 653-62.

Assalian P, Rosengarten MD, Phillips R. Comparative Trial of Trimipramine versus Doxepin in depressed hospitalised Patients. Drugs 1989: 38, 32-34.

Baumann P, Jonzier Perey M, Koeb L, Küpfer A, Tinguely D, Schopf J. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986: 1(2), 102-112.

Benkert O und Hippius H. Antidepressiva. In: Kompendium der Psychiatrischen Pharmakotherapie 2003, S. 1 – 52. Springer Verlag Berlin – Heidelberg, 2003.

Berger M und Gastpar M. Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci 1996: 246(5), 235-239.

Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: Clinical aspects. Acta Psychiatr Scand 1997: 96, 14-21.

Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992: 51(4), 388-397.

Bertz RJ und Grannemann GR. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clin Pharmacokinet 1997: 32(3), 210-258.

Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997: 7, 51-58.

Bogaert MG, Rosseel MT, Deberdt R, Vranckx C. Plasma Levels of the cis- and trans-Isomers of Doxepin and Desmethyldoxepin after Administration of Doxepin to Patients. Arzneimittel Forschung1981: 31, 113-115.

Bolaji OO, Coutts RT, Baker GB. Metabolism of trimipramine in vitro by human CYP2D6 isozyme. Res Commun Chem Pathol Pharmacol 1993: 82, 111-120.

Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002: 3 (2), 229-243.

Brockmöller J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000: 1(2), 125-151.

Brosen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986: 40(5), 543-549.

Burke MJ and Preskorn SH. Therapeutic drug monitoring of antidepressants. Clin Pharmacokinet 1999: 37(2), 147-165.

Coutts RT und Urichuk LJ. Polymorphic Cytochrome P450 and Drugs Used in Psychiatry. Cell Molr Neurobiol 1999: 19(3), 325-54.

Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, et al.. Nomenclature for human CYP2D6. Pharmacogenetics 1996: 6(3), 193-201.

de Groot MJ, Bijloo GJ, Martens BJ, van Acker FA, Vermeulen NP. A refined substrate model for human cytochrome P450 2D6. Chem Res Toxicol 1997: 10(1), 41-48.

de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P450 isozymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol Exp Ther 1990: 253(1), 387-393.

Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. Identi fi ca tion and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001: 60(2), 382-7.

Eap CB, Bender S, Gastpar M, Fischer W, Haarmann C, Powell K, Jonzier-Perey M, Cochard N, Bau mann P. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19 and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000: 22(2), 209-214.

Eap CB, Laurian S, Souche A, Koeb L, Reymond P, Buclin T, Baumann P. Influence of Quinidine on the Pharmakokinetics of Trimipramine and on Its Effect on the Waking EEG of Healthy Volunteers. Neuropsychobiology 1992: 25(4), 214-220.

Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastpar M. Trimipramine - an atypical neuroleptic? Int Clin Psychopharmacol 1991: 6(3), 147-53.

Ereshefsky L, Tran-Johnson T, Davis CM, LeRoy A. Pharmakokinetic factors affecting antidepressant Drug Clearance and clinical effect: Evaluation of Doxepin and Imipramine - New Data and Review. Clin Chem 1988: 34(5), 863-880.

Evans WE und McLeod HL. Pharmacogenomics - Drug disposition, drug targets, and side effects. N Engl J Med 2003: 348(6), 538-549.

Fachinformation Aponal ® 75/ Aponal® 100 (1999). Fa. Roche, Grenzach-Wyhlen, Deutschland.

Faulkner RD, Pitts WM, Lee CS, Lewis WA, Fann WE. Multiple-dose doxepin kinetics in depressed patients. Clin Pharmacol Ther 1983: 34(4), 509-515.

Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998: 284(1), 356-61.

Fraser AD, Isner AF, Perry RA. Distribution of trimipramine and its major metabolites in a fatal over dose case. J Anal Toxicol 1987: 11(4), 168-170.

Ghabrial H, Prakash C, Tacke UG, Blair IA, Wilkinson GR. Geometric isomerization of doxepin during its N-demethylation in humans. Drug Metab Dispos 1991: 19(3), 596-599.

Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol 1997: 43(2), 137-44.

Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, Wolf CR. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997: 27(1), 111-125.

Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001: 52(4), 349-55.

Goldstein JA und de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994: 4(6), 285-299.

Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988: 331(6155), 442-446.

Gonzelez FJ und Nebert DW. Evolution of the P450 gene superfamily: animal plant "warfare", mole cu lar drive and human genetic differences in drug oxidation. Trends Genet 1990: 6, 182-186.

Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from com parative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992: 267(1), 83-90.

Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-Megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995: 28(2), 328-332.

Gross G, Xin X, Gastpar M. Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacology 1991: 30(11), 1159-66.

Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996: 333(2), 447-458.

Haritos VS, Ghabrial H, Ahokas JT, Ching MS. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics 2000: 10(7), 591-603.

Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C. N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharma Res 2002: 19(7), 1035-1038.

Hauser K, Olpe HR, Jones RS . Trimipramine, a tricyclic antidepressant exerting atypical actions on the central noradrenergic system. Eur J Pharmacol1985: 111(1), 23-30.

Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998: 249(3), 838-843.

Hrdina PD, Bakish D, Swenson S, Lapierre YD. Cis- and Trans-Isomers of Doxepin and Desmethyl doxepin in the Plasma of Depressed Patients Treated with Doxepin. Ther Drug Monit 1990: 12(2), 129-133.

Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA. An additional defective allele, CYP2C19*5, contributes to the S-me pheny toin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998: 8(2), 129-35.

Ieiri I, Tainaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, Ninomiya H, Ohmori S, Kitada M, Tashiro N, Higuchi S, Otsubo K. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 2000: 22(3), 237-44.

Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 1999: 20(8), 342-349.

Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996: 6(4), 351-355.

Jones BC, Hawksworth G, Horne VA, Newlands A, Morsman J, Tute MS, Smith DA. Putative active site model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab Dispos 1996: 24, 260-266.

Jones JP, He M, Trager WF, Rettie AE. Three dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 1996. 24(1), 1-6.

Joyce PR, Sharman JR. Doxepin plasma concentrations in clinical practice: could there be a pharma cokinetic explanation for low concentrations? Clin Pharmacokinet 1985: 10(4), 365-370.

Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001: 11(9), 803-8.

Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlor pheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999: 9(1), 71-80.

Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D6) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989: 45(6), 889-904.

Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmöller J. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001: 104(3), 173-192.

Kirchheiner J, Nickchen K, Bauer M, Wong M-L, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004: 9(5), 442-73.

Kirchheiner J, Sasse J, Meineke I, Roots I, Brockmöller J. Trimipramine pharmacokinetics after intra venous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics 2003: 13, 721-728.

Koyama E, Tanaka T, Chiba K, Kawakatsu S, Morinobu S, Totsuka S, Ishizaki T. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 1996: 16(4), 286-293.

Koymans LM, Vermeulen NP, Baarslag A, Donne-Op den Kelder GM A preliminary 3D model for cyto chrome P450 2D6 constructed by homology model building. J Comput Aided Mol Des 1993: 7(3), 281-289.

Kupfer A und Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984: 26(6), 753-9.

Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as a cause of diphenyl hy dan toin toxicity. Neurology 1964: 14, 542-548.

Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G. Gene-environment interaction in parkinson´s disease. The case of CYP2D6 gene polymorphism. Adv Neurol 1996: 69, 61-72.

Lapierre YD. A Review of Trimipramine: 30 years of clinical use. Drugs 1989: 38, 17-24.

Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998: 279(15), 1200-1205.

Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002: 12(3), 251-263.

Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W. Doxepin plasma concentrations: is there really a therapeutic range? J Clin Psychopharmacol 2002: 21(4), 432-439.

Lohse MJ und Müller-Oerlinghausen B. Psychopharmaka. In : Schwabe U/ Paffrath D (Hrsg.), Arznei ver ord nungs-Report 1999. S. 537 ff.. Springer-Verlag Berlin – Heidelberg, 1999.

Loo H, Benyacoub AK, Rovei V, Altamura CA, Vadrot M, Morselli PL. Long-term monitoring of tricyclic antidepressant plasma concentrations. Br J Psychiatry 1980: 137, 444-451.

Luchins DJ, Oliver AP, Wyatt RJ. Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia 1984: 25(1), 25-32.

Madsen H, Hansen TS, Brosen K. Imipramine metabolism in relation to the sparteine oxidation polymorphism - a family study. Pharmacogenetics 1996: 6(6), 513-519.

Madsen H, Nielsen KK, Brosen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms - a population study. Br J Clin Pharmacol 1995: 39(4), 433-439.

Madsen H, Rasmussen BB, Brosen K. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther 1997: 61(3), 319-324.

Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorhpic hydroxylation of debrisoquine in man. Lancet 1977: 2(8038), 584-586.

Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P4502C9: An approach using designed tienilic acid derivatives and molecular modelling. Biochemistry 1995: 34, 10365-10375.

Martinez C, Agundez JA, Gervasini G, Martin R, Benitez J. Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 1997: 7(2), 85-93.

Meatherall RC, Guay DR, Nokes JM, Keenan JR. Toxicological findings in a death resulting from the in gestion of trimipramine. J Forensic Sci 1983: 28(4), 1023-1029.

Meehan RR, Gosden JR, Rout D, Hastie ND, Friedberg T, Adesnik M, Buckland R, van Heyningen V, Fletcher J, Spurr NK, et al. Human cytochrome P-450 PB-1: a multigene family involved in me phe nytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 1988: 42(1), 26-37.

Mellström B, Bertilsson L, Sawe J, Schulz HU, Sjoqvist F E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981: 30(2), 189-193.

Mellström B, Sawe J, Bertilsson L, Sjoqvist F. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther 1986: 39(4), 369-371.

Meyer-Barner M, Meineke I, Schreeb KH, Gleiter CH. Pharmacokinetics of doxepin and desmethyldo xe pin - an evaluation with the population approach. Eur J Clin Pharmacol 2002: 58(4), 253-257.

Midha KK, Hubbard JW, McKay G, Hawes EM, Korchinski ED, Gurnsey T, Cooper JK, Schwede R. Stereo selective pharmacokinetics of doxepin isomers. Eur J Clin Pharmacol 1992: 42(5), 539-544.

Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998: 45(6), 525-538.

Möller HJ. Therapy resistance to antidepressive drugs: risk factors and treatment possibilities. Nervenarzt 1991: 62(11), 654-669.

Mouret J, Lemoine P, Minuit MP, Sanchez P, Taillard J. Sleep Polygraphic Effects of Trimipramine in depressed Patients: Preliminary Report. Drugs 1989: 38, 14-16.

Musa MN. Nonlinear kinetics of trimipramine in depressed patients. J Clin Pharmacol 1988: 29(8), 1038-1039.

Musshoff F, Schmidt P, Madea B. Fatality caused by a combined trimipramine-citalopram intoxication. Forensic Sci Int 1999: 106(2), 125-131.

Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997: 60(2), 265-271.

Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, et al. The P450 gene superfamily: recommended nomen clature. DNA 1987: 6(1), 1-11.

Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003: 64 Suppl. 1, 5-12.

Nielsen KK, Brosen K, Gram LF. Steady-state plasma levels of clomipramine and its metabolites: Im pact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antide pressant Group. Eur J Clin Pharmacol 1992: 43(4), 405-411.

Pecknold JC und Luthe L. Trimipramine, Anxiety, Depression and Sleep. Drugs 1989: 38 Suppl. 1, 25-31.

Petersen RC und Richelson E. Anticholinergic Activity of Imipramine and Some Analogs at Muscarinic Receptors of Cultured Mouse Neuroblastoma Cells. Psychopharmacology 1982: 76(1), 26-28.

Pinder RM, Brogden RN, Speight TM, Avery GS. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977: 13(3), 161-218.

Preskorn SH, Dorey RC, Jerkovich GS. Therapeutic drug monitoring of tricyclic antidepressants. Clin Chem 1988: 34(5), 822-828.

Randrup A und Bræstrup C. Uptake Inhibition of Biogenic Amines by Newer Antidepressant Drugs: Relevance to the Dopamine Hypothesis of Depression. Psychopharmacology 1977: 53(3), 309-314.

Rannug A, Alexandrie AK, Persson I, Ingelman-Sundberg M. Genetic polymorphis of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 1995: 37(1), 25-36.

Rao ML, Deister A, Laux G, Staberock U, Höflich G, Möller HJ. Low serum levels of tricyclic anti de pressant in amitritypline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry 1996: 29(3), 97-102.

Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990: 252(1), 442-447.

Richelson E und Nelson A. Antagonism by Antidepressants of Neurotransmitter Receptors of normal human brain In Vitro. J Pharmacol Exp Ther 1984: 230(1), 94-102.

Rüther E. Depression, Circadian Rhythms and Trimipramine. Drugs 1989: 38 Suppl 1, 1-3.

Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997: 60(2), 284-295.

Scott J und Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979: 28(1), 41-51.

Seifritz E, Holsboer-Trachsler E, Hemmeter U, Eap CB, Baumann P. Incresed trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol 1994: 4(1), 15-20.

Settle EC Jr und Ayd FJ Jr. Trimipramine: twenty years´ worldwide clinical experience. J Clin Psychiatry 1980: 41(8), 266-274.

Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Che micals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994: 270(1), 414-423.

Shu YZ, Hubbard JW, Cooper JK, McKay G, Korchinski ED Kumar R, Midha KK. The identification of urinary metabolites of doxepin in patients. Drug Metab Dispos 1990: 18(5), 735-741.

Skjelbo E, Gram LF, Brosen K. The N-demethylation of imiramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. Br J Clin Pharmacol 1993: 35(3), 331-334.

Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997: 51(5), 395-398.

Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997: 7(5), 361-367.

Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996: 6(5), 429-439.

Suckow RF und Cooper TB. Determination of Trimipramine and Metabolites in Plasma by Liquid Chro ma to graphy with Electrochemical Detection. J Pharm Sci 1984. 73(12), 1745-48.

Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide poly mor phism. Pharmacogenetics 1996: 6(4), 341-349.

Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000: 10(2), 95-104.

Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation In-vitro. J Clin Pharmacol 1998: 38(2), 112-121.

Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, von Moltke LL, Graf JA, Mertzanis P, Cor bett KE, Rodriguez MC, Shader RI, Greenblatt DJ. Relative contribution of CYP3A to ami trip tyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 2001: 41(10), 1043-1054.

von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Wright CE, Harmatz JS, Shader RI. Human cyto chromes mediating N-demethylation of fluoxetine In-vitro. Psychopharmacology 1997: 132(4), 402-7.

Waldmeier PC. Effects of antidepressant drugs on dopamine uptake and metabolism. J Pharm Pharmacol 1982: 34(6), 391-394.

Whrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 1993: 306(1), 240-5.

Wiegand M und Berger M. Action of Trimipramine on Sleep and Pituitary Hormone Secretion. Drugs 1989: 38 Suppl 1, 35-42.

Wolf CR und Smith G. Pharmacogenetics. Br Med Bull 1999: 55(2), 366-386.

Wrighton SA und Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992: 22(1), 1-21.

Webseiten; UT Memphis, Department Of Biochemistry 1993: Cytochrome P450 homepage.; Karolinska Institutet National Institute Of Environmental Medicine 1999: Human cytochrome P450 (CYP) allele nomenclature committee.; UT Indiana, Department Of Medicine 2002: Cytochrome P450 drug int

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: